Latest Lead News

Tryptamine Therapeutics reported a $5.33 million loss for FY25 while progressing key clinical trials of its psychedelic therapies and strengthening its leadership team. The company secured $6 million in funding and launched a world-first trial targeting Binge Eating Disorder.

Frontier Digital Ventures reported a 5% decline in consolidated revenue to A$33.3 million for the first half of 2025, driven by challenges in its Latin American property portal Infocasas. However, the company achieved a robust 71% increase in EBITDA, reflecting improved operational efficiency and strong associate performance in Pakistan.

LTR Pharma’s FY25 results reveal a transformative year highlighted by SPONTAN’s rapid absorption and strategic partnerships that pave the way for US market entry.

LTR Pharma Limited (ASX, LTP) reported significant progress in FY25, advancing its novel intranasal treatments for erectile dysfunction and expanding its commercial footprint in Australia and the US. The company secured key partnerships and capital raises, positioning itself for regulatory milestones and global market entry.

PointsBet Holdings Limited reported a 6% increase in revenue to $261.4 million for FY2025, alongside a significant reduction in net loss and its first full year of EBITDA profitability. The company’s Australian operations delivered record results while Canadian growth accelerated, setting a positive trajectory for the future.

AF Legal Group has reported a record-breaking FY25 with revenue up 27% to $27.6 million and a 77% jump in normalised profit before tax. The firm’s strategic acquisitions and operational improvements set a positive tone for FY26 growth.

AF Legal Group Ltd reported a robust 27% increase in revenue to $27.6 million for FY25, propelled by key acquisitions and operational expansion, despite one-off costs impacting statutory profits.

Hearts and Minds Investments Limited (HM1) reported a stellar FY25 with total comprehensive income soaring to $124.8 million, nearly doubling the prior year, alongside a dividend increase and sustained philanthropic commitments.

Lynas Rare Earths has successfully completed a A$750 million institutional placement, strengthening its balance sheet to fund ambitious growth plans under its Towards 2030 strategy.

Volt Group Limited reports a 38% surge in EcoQuip revenue alongside steady progress in zero-emission technologies, positioning itself strongly in the clean energy transition.

PYC Therapeutics has reported promising safety data from the initial phase of its clinical trial for PYC-003, an RNA therapy targeting the root cause of Polycystic Kidney Disease. The findings, presented at the ANZSN conference, highlight the drug’s tolerability in healthy volunteers, paving the way for further clinical development.

Memphasys Limited reported a net loss of AUD 4.94 million for FY25 while accelerating commercial efforts for its Felix System and advancing its RoXsta diagnostics platform.